The efficacy of progesterone in achieving successful pregnancy: I. Prophylactic use during luteal phase in anovulatory women

  • Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
  • Cooper University Hospital ROR
  • Thomas Jefferson University ROR

International Journal of Fertility, 32(2), 135-138

Source

Abstract

We have previously shown that prophylactic supplementation of progesterone beginning in the luteal phase of patients treated with human menopausal gonadotropins (hMG) could reduce the risk of spontaneous abortions. The present study was initiated with 100 patients to evaluate the efficacy of a new progesterone therapeutic regime in patients requiring either hMG or clomiphene citrate. A significantly decreased risk of spontaneous abortion (6% vs. 28%) was seen in 50 patients prophylactically treated with progesterone as compared with 50 control patients. The progesterone regimen was then tried on 566 consecutive patients who were treated and conceived with hMG or clomiphene citrate, and approximately the same risk (6.2% by 20 weeks) was found. This incidence of spontaneous abortion is even less than the accepted risk for the general population.

Topics

progesterone supplementation luteal phase anovulatory women pregnancy, Check JH prophylactic progesterone spontaneous abortion prevention, progesterone after clomiphene citrate hMG reduce miscarriage, luteal phase progesterone supplementation ovulation induction, human menopausal gonadotropin progesterone miscarriage rate, prophylactic progesterone spontaneous abortion risk reduction, progesterone regimen clomiphene citrate conceived patients, luteal support ovulation induction pregnancy outcomes, progesterone supplementation decrease spontaneous abortion rate, anovulatory infertility ovulation induction luteal phase support

Cite this article

Check, J. H., Chase, J. S., Wu, C. H., Adelson, H. G., Teichman, M., & Rankin, A. (1987). The efficacy of progesterone in achieving successful pregnancy: I. Prophylactic use during luteal phase in anovulatory women. *International journal of fertility*, *32*(2), 135-138.

Related articles